Monthly Archives: August 2012

The Increasing Value of Medical Science Liaisons

Can’t get your sales rep into that academic medical center? Try sending a medical science liaison (MSL). A new study from Industry Standard Research (ISR) found that MSLs enjoy better access and higher levels of trust among oncologists. Docs also want different kinds of information from MSLs, according to the study findings.
Posted in Advertising, Marketing, Medical Education, patient education, Sales, Strategy | Tagged , , | 2 Comments

AIDS: ARV Optimism Tempered by Home Truths

The prospect that antiretroviral drugs could prevent HIV infection in high-risk populations was the big news emerging from last month’s International AIDS Conference in Washington, DC. But the news raises the tricky ethical question of whether the US should spend $11,000 per patient to keep uninfected individuals healthy, when funds are lacking to provide life-saving […]
Posted in FDA, Guest Blog, healthcare | Tagged , , , , , , , | Leave a comment

Three Questions to Ask About Your Life Sciences Patents

By Marian T. Flattery and Michael J. Flibbert The decisions you make today about patents – what, when and where to file – could have implications tantamount to billions of dollars in R&D investment and sales over the next two decades. Given the increasing importance of lifecycle management in the context of increasing generic usage […]
Posted in IP, Legal, R&D | Tagged , , | Leave a comment

Challenges in the March Toward an AIDS-Free Generation

FDA’s approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS.
Posted in Biotech, Events, FDA, healthcare, Market Access, Patient Communication, patient compliance, patient education, pricing, Regulatory, Safety | Tagged , , , , , , , | Leave a comment
  • Categories

  • Meta